Farallon Capital Management LLC Veracyte, Inc. Transaction History

Farallon Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$21.94 - $42.51 $3.48 Million - $6.74 Million	-158,658 Reduced 83.0%	32,500 $896,000
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $214,230 - $319,297	5,936 Added 3.2%	191,158 $7.88 Million
Q3 2021 Nov 15, 2021	SELL	$35.62 - $52.97 $23.7 Million - $35.2 Million	-664,778 Reduced 78.21%	185,222 $8.6 Million
Q2 2020 Aug 14, 2020	SELL	$19.49 - $28.11 $10.2 Million - $14.8 Million	-525,000 Reduced 38.18%	850,000 $22 Million
Q1 2020 May 15, 2020	BUY	$16.13 - $30.17 $6.05 Million - $11.3 Million	375,000 Added 37.5%	1,375,000 $33.4 Million
Q3 2019 Nov 14, 2019	BUY	$23.87 - $30.93 $15.5 Million - $20.1 Million	650,000 Added 185.71%	1,000,000 $24 Million
Q2 2019 Aug 14, 2019	BUY	$22.1 - $28.56 $7.74 Million - $10 Million	350,000 New	350,000 $9.98 Million

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.